Mucus Relief Sinus Severe Congestion Relief Tablet, Coated
NDC Package 68016-549-20

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is approaching its end of marketing date. An upcoming end of marketing date means the product has been delisted but will remain in the NDC database until the end of marketing date is reached. In most cases, the FDA advises firms to use the expiration date of the last lot produced as the end marketing date, reflecting the possibility that the product may still be available even after manufacturing has stopped.

Mucus Relief Sinus Severe Congestion Relief (acetaminophen, guaifenesin, and phenylephrine hydrochloride) tablets is do not take more than directed (see Overdose warning) do not take more than 12 caplets in any 24-hour periodadults and children 12 years and older:  take 2 caplets every 4 hourschildren under 12 years of age:  do not use. This formulation utilizes a tablet, coated delivery system. Marketed by Chain Drug Consortium, this product is identified by NDC 68016-549 and is authorized under FDA application M012.

Identification & Billing

NDC Package Code
68016-549-20
Package Description
2 BLISTER PACK in 1 CARTON / 10 TABLET, COATED in 1 BLISTER PACK
Product Code
68016-549
11-Digit Billing Format
68016054920
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
2 EA
RxNorm Crosswalk
  • RxCUI: 1243679 - acetaminophen 325 MG / guaiFENesin 200 MG / phenylephrine HCl 5 MG Oral Tablet
  • RxCUI: 1243679 - acetaminophen 325 MG / guaifenesin 200 MG / phenylephrine hydrochloride 5 MG Oral Tablet
  • RxCUI: 1243679 - APAP 325 MG / GG 200 MG / phenylephrine hydrochloride 5 MG Oral Tablet
  • RxCUI: 1243679 - APAP 325 MG / Guaifenesin 200 MG / Phenylephrine Hydrochloride 5 MG Oral Tablet

Clinical Specifications

Proprietary Name
Mucus Relief Sinus Severe Congestion Relief
Non-Proprietary Name
Acetaminophen, Guaifenesin, And Phenylephrine Hydrochloride
Substance Name
Acetaminophen; Guaifenesin; Phenylephrine Hydrochloride
Dosage Form
Tablet, Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is covered with a designated coating.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Pharmacologic Class
Usage Information
Do not take more than directed (see Overdose warning) do not take more than 12 caplets in any 24-hour periodadults and children 12 years and older:  take 2 caplets every 4 hourschildren under 12 years of age:  do not use

Regulatory & Marketing

Labeler Name
Chain Drug Consortium
Product Type
Human Otc Drug
FDA Application #
M012
Marketing Category
OTC MONOGRAPH DRUG -
Start Marketing Date
09-01-2014
End Marketing Date
07-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68016-549-20 identifies a specific commercial package of 2 blister pack in 1 carton / 10 tablet, coated in 1 blister pack of Mucus Relief Sinus Severe Congestion Relief, a human over the counter drug labeled by Chain Drug Consortium. This product is billed for "EA" each discreet unit and contains an estimated amount of 2 billable units per package. This tablet, coated is formulated for oral use and contains acetaminophen; guaifenesin; phenylephrine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Chain Drug Consortium on September 01, 2014.

How is this Chain Drug Consortium product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68016054920. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 2 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
68016-549-20
11-Digit CMS (5-4-2)
68016-0549-20

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.